Impact of IFNL4 genetic variants on sustained virologic response and viremia in hepatitis C virus genotype 3 patients by Pedergnana, V, Irving, W, Barnes, E, McLauchlan, J, Spencer, C

Impact of virus subtype and host IFNL4 genotype on large-scale RNA structure formation in the genome of hepatitis C virus by Simmonds, P, Kuypers, L, Irving, WL, McLauchlan, J, Cooke, GS, Barnes, E, Ansari, MA

Human endogenous retrovirus-K HML-2 integration within RASGRF2 is associated with intravenous drug abuse and modulates transcription in a cell-line model by Karamitros, T, Hurst, T, Marchi, E, Karamichali, E, Georgopoulou, U, Mentis, A, Riepsaame, J, Lin, A, Paraskevis, D, Hatzakis, A, McLauchlan, J, Lin, A, Katzourakis, A, Magiorkinis, G

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. by Cheung, M, Walker, A, Hudson, B, Verma, S, McLauchlan, J, Mutimer, D, Brown, A, Gelson, W, MacDonald, D, Agarwal, K, Foster, G, Irving, W, Uk, H

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis by Foster, G, Irving, W, Cheung, M, Walker, A, Hudson, B, Verma, S, McLauchlan, J, Mutimer, D, Brown, A, Gelson, W, MacDonald, D, Agarwal, K, HCV Research, UK

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure by Smith, DA, Fernandez-Antunez, C, Magri, A, Bowden, R, Chaturvedi, N, Fellay, J, McLauchlan, J, Foster, GR, Irving, WL, Barnes, E, Simmonds, P, Pedergnana, V, Ramirez, S, Bukh, J, Ansari, MA

Public Health England HCV Resistance Group: overview and consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection by Bradshaw, D, Mbisa, J, Geretti, A, Healy, B, Cooke, G, Foster, G, Thomson, E, McLauchlan, J, Agarwal, K, Sabin, C, Mutimer, D, Moss, P, Irving, W, Barnes, E, The Hepatitis C Trust, UK

Amino acid substitutions in genotype 3a hepatitis C virus polymerase protein affect responses to sofosbuvir by Wing, P, Jones, M, Cheung, M, Dasilva, S, Bamford, C, Jason Lee, W, Aranday-Cortes, E, Da Silva Filipe, A, McLauchlan, J, Smith, D, Irving, W, Cunningham, M, Ansari, A, Barnes, E, Foster, G

Effect of resistance associated substitutions on retreatment of HCV infected patients with prior failure to direct acting antiviral therapy by Smith, D, Bradshaw, D, Mbisa, J, Manso, C, Bibby, D, Singer, J, Thomson, E, Filipe, A, Aranday-Cortes, E, Ansari, A, Brown, A, Hudson, E, Benselin, J, Healy, B, McLauchlan, J, Barnes, E, Irving, W

Interpreting viral deep sequencing data with GLUE by Singer, J, Thomson, E, Hughes, J, Aranday-Cortes, E, McLauchlan, J, Da Silva Filipe, A, Tong, L, Manso, C, Gifford, R, Robertson, D, Barnes, E, Ansari, M, Mbisa, J, Bibby, D, Bradshaw, D, Smith, D

Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy by Smith, DA, Bradshaw, D, Mbisa, J, Manso, CF, Bibby, D, Singer, J, Thomson, E, Filipe, A, Aranday-Cortes, E, Ansari, MA, Brown, A, Hudson, E, Benselin, J, Healy, B, Troke, P, McLauchlan, J, Barnes, E, Irving, WL

In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control by Ansari, A, Marchi, E, Ramamurthy, N, Aschenbrenner, D, Morgan, S, Hackstein, C-P, Lin, S-K, Bowden, R, Sharma, E, Pedergnana, V, Venkateswaran, S, Kugathasan, S, Mo, A, Gibson, G, Cooke, G, McLauchlan, J, Baillie, JK, Teichmann, S, Mentzer, A, Knight, J, Todd, J, Hinks, T, Barnes, E, Klenerman, P, Uhlig, H

Highly diverse Hepatitis C strains detected in Sub‐Saharan Africa have unknown susceptibility to direct‐acting antiviral treatments by Davis, C, Mgomella, G, Da Silva Filipe, A, Frost, E, Giroux, G, Hughes, J, Hogan, C, Kaleebu, P, Asiki, G, McLauchlan, J, Niebel, M, Ocama, P, Pomila, C, Pybus, O, Pépin, J, Simmonds, P, Singer, J, Sreenu, V, Wekesa, C, Young, E, Murphy, D, Sandhu, M, Thomson, E

Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus by Ansari, M, Pedergnana, V, Ip, C, Magri, A, Von Delft, A, Bonsall, D, Chaturvedi, N, Bartha, I, Smith, D, Nicholson, G, McVean, G, Trebes, A, Piazza, P, Fellay, J, Cooke, G, Foster, G, STOP-HCV Consortium, Hudson, E, McLauchlan, J, Simmonds, P, Bowden, R, Klenerman, P, Barnes, E, Spencer, C

Full genome sequence and sfRNA interferon antagonist activity of Zika virus from Recife, Brazil by Donald, C, Brennan, B, Cumberworth, S, Rezelj, V, Clark, J, Cordeiro, M, Freitas de Oliveira França, R, Pena, L, Wilkie, G, Da Silva Filipe, A, Davis, C, Hughes, J, Varjak, M, Selinger, M, Zuvanov, L, Owsianka, A, Patel, A, McLauchlan, J, Lindenbach, B, Fall, G, Sall, A, Biek, R, Rehwinkel, J, Schnettler, E, Kohl, A

Interferon lambda 4 impacts the genetic diversity of hepatitis C virus by Ansari, M, Aranday-Cortes, E, Ip, C, Da Silva Filipe, A, Lau, S, Bamford, C, Bonsall, D, Trebes, A, Piazza, P, Sreenu, V, Cowton, V, Stop-Hcv Consortium, Ball, J, Barnes, E, Burgess, G, Cooke, G, Dillon, J, Foster, G, Gore, C, Guha, N, Halford, R, Holmes, C, Hudson, E, Hutchinson, S, Irving, W, Khakoo, S, Klenerman, P, Martin, N, Mbisa, T, McKeating, J, McLauchlan, J, Miners, A, Murray, A, Shaw, P, Simmonds, P, Smith, S, Spencer, C, Thomson, E, Troke, P, Vickerman, P, Zitzmann, N, Hudson, E, Bowden, R, Patel, A, Foster, G, Irving, W, Agarwal, K, Thomson, E, Simmonds, P, Klenerman, P, Holmes, C, Barnes, E, Spencer, C, McLauchlan, J, Pedergnana, V

Comparison of next generation sequencing technologies for the comprehensive assessment of full-length hepatitis C viral genomes. by Thomson, E, Ip, C, Badhan, A, Christiansen, M, Adamson, W, Ansari, M, Bibby, D, Breuer, J, Brown, A, Bowden, R, Bryant, J, Bonsall, D, Da Silva Filipe, A, Hinds, C, Hudson, E, Klenerman, P, Lythgow, K, Mbisa, J, McLauchlan, J, Myers, R, Piazza, P, Roy, S, Trebes, A, Vattipally, S, Witteveldt, J, STOP-HCV consortium, Barnes, E, Simmonds, P

Comparison of next-generation sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes by Thomson, E, Ip, C, Badhan, A, Christiansen, M, Adamson, W, Ansari, M, Bibby, D, Breuer, J, Brown, A, Bowden, R, Bryant, J, Bonsall, D, Da Silva Filipe, A, Hinds, C, Hudson, E, Klenerman, P, Lythgow, K, Mbisa, J, McLauchlan, J, Myers, R, Piazza, P, Roy, S, Trebes, A, Sreenu, V, Witteveldt, J, Barnes, E, Simmonds, P

Cost-effectiveness analysis of baseline testing for resistance-associated polymorphisms to optimize treatment outcome in genotype 1 noncirrhotic treatment-naïve patients with chron... by Fawsitt, C, Vickerman, P, Cooke, G, Barnes, E, Ball, J, Brainard, D, Burgess, G, Dillon, J, Foster, G, Gore, C, Guha, N, Halford, R, Whitby, K, Holmes, C, Howe, A, Hudson, E, Hutchinson, S, Irving, W, Khakoo, S, Klenerman, P, Martin, N, Massetto, B, Mbisa, T, McHutchison, J, McKeating, J, McLauchlan, J, Miners, A, Murray, A, Shaw, P, Simmonds, P, Spencer, C, Thomson, E, Zitzmann, N, Welton, N